



## ADASTRA HOLDINGS LTD. ENGAGES HYBRID FINANCIAL LTD.

### FOR IMMEDIATE RELEASE

Langley, BC, October 21, 2021 – Adastra Holdings Ltd. (formerly Phyto Extractions Inc.) (CSE: XTRX) (FRA: D2EP) (“**Adastra**”, or the “**Company**”) is pleased to announce that it has retained Hybrid Financial Ltd. (“**Hybrid**”) to provide marketing services to the Company. Hybrid has been engaged to heighten market and brand awareness for Adastra and to broaden the Company's reach within the investment community.

Hybrid has agreed to comply with all applicable securities laws and the policies of the Canadian Securities Exchange in providing the services.

Hybrid has been engaged by the Company for an initial period of six (6) months starting May 3, 2021 (the “**Initial Term**”) and then shall be renewed automatically for successive three (3) month periods thereafter, unless terminated by the Company in accordance with the agreement. Hybrid will be paid a monthly fee of \$22,500, plus applicable taxes, during the Initial Term.

#### **About Adastra Holdings Ltd.:**

Founded in 2018 and formerly known as Phyto Extractions Inc., Adastra is a leading manufacturer and supplier of innovative ethnobotanical and cannabis science products designed for the adult-use and medical markets and forward-looking therapeutic applications. Adastra is renowned throughout Canada for its popular line of Phyto Extractions branded cannabis concentrate products available on shelves at over 1,400 adult-use retailers across the country. The Company also operates Adastra Labs, a 13,500 sq. ft. agricultural-scale Health Canada licensed facility located in Langley, BC., focused on extraction, distillation, and manufacturing of cannabis-derived products. Adastra has now successfully taken the first steps in becoming a licensed cultivator, tester, extractor, and seller of controlled substances, including Psilocybin, Psilocin, MDMA, N, N-Dimethyltryptamine (DMT), 5- MeO-DMT, and LSD by applying for a Controlled Substances Dealer's Licence, which is under review by Health Canada. Pending Health Canada approval, Adastra is poised to be a drug formulation and development leader in this emerging sector. In addition, with the recent acquisition of 1225140 B.C. Ltd., doing business as PerceiveMD, Adastra operates a multidisciplinary centre for medical cannabis and psychedelic therapies, working alongside doctors and healthcare professionals within the regulated environment to help create efficacious remedies that address the actual needs of patients.

#### **About Hybrid Financial Ltd.:**

Hybrid is a sales and distribution company that actively connects issuers to the investment community across North America. Using a data driven approach, Hybrid provides its clients with comprehensive coverage of both American and Canadian markets. Hybrid has offices in Toronto and Montreal.



**ON BEHALF OF THE BOARD  
ADAstra HOLDINGS LTD. (CSE: XTRX)**

Donald Dinsmore, Chief Operating Officer  
P: (778) 715-5011, E: Donald@adastralabs.com

Cody Simpson, Communications Manager  
P: (778) 715-5011, E: cody@adastraholdings.ca

*The Canadian Securities Exchange has not reviewed or approved the contents of this news release.*